A Study to Collect Health Related Data and Biological Samples that will Enable Researchers to Understand the Cause of Cryptogenic New-onset Refractory Status Epilepticus

Overview

About this study

The purpose of this study is to establish a collection of health related data and biological samples that will enable researchers to understand the cause of cryptogenic new-onset refractory status epilepticus (NORSE), to identify the key determinants of outcome and to determine the best management strategy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

SE refractory to first and second‐line therapy
No etiology found in the first 24 hours despite extensive work‐up
Age > 2 years

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Alejandro Rabinstein, M.D.	Closed for enrollment	Contact information: Amy Headlee CCRP, SOCRA (507) 422-0406 Headlee.Amy@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alejandro Rabinstein, M.D.

Closed for enrollment

Contact information:

Amy Headlee CCRP, SOCRA

(507) 422-0406

Headlee.Amy@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials